Clinical application evaluation of cetuximab based on real-world data
Objective To conduct a clinical application evaluation of cetuximab based on real-world data,explore the content and methods of the clinical comprehensive evaluation of antitumor drugs,and provide a basis for rational clinical use and drug-related decision-making.Methods According to the guidelines of clinical application evaluation,cetuximab was evaluated in six dimensions based on real-world data.Results The evaluation results of various dimensions showed that most adverse reactions of cetuximab were not significantly different from bevacizumab and common chemotherapy regimens,but the incidence of rash was significantly higher than the others.In terms of efficacy,there is no significant difference be-tween cetuximab and bevacizumab,but the remission rate of 5%is much lower than the clinical trial results.After propensity score matching,there was no significant difference in the total cost of the bevacizumab regimen,but it was significantly high-er than the total cost of the common chemotherapy regimen.Cetuximab can be used for head and neck squamous cell carci-noma which can fill the clinical treatment gap and meet the clinical requirements.It is analogous to other similar anti-tumor drugs and has no obvious advantages over the current suitability,but availability and affordability of cetuximab in Shandong is relatively poor.Conclusion Compared with bevacizumab,cetuximab has no significant difference in safety,efficacy,e-conomy,and suitability,and has advantages in innovation and slightly poor accessibility.
Clinical application evaluationColorectal cancerCetuximabReal-world data
国家科技期刊平台
NSTL
万方数据
